References
- Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006;27:352–7.
- Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002;14:103–10.
- Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499–511.
- Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002;168:554–61.
- Shi H, Kokoeva MV, Inouye K, TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015–25.
- Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675–80.
- Chow JC, Young DW, Golenbock DT, Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689–92.
- Kurt-Jones EA, Popova L, Kwinn L, Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1:398–401.
- Arbour NC, Lorenz E, Schutte BC, TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187–91.
- Kiechl S, Lorenz E, Reindl M, Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347: 185–92.
- Ohashi K, Burkart V, Flohé S, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164:558–61.
- Okamura Y, Watari M, Jerud ES, The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276:10229–33.
- Schröder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 2005;5:156–64.
- Candore G, Colonna-Romano G, Balistreri CR, Biology of longevity: role of the innate immune system. Rejuvenation Res 2006;9:143–8.
- Ozturk A, Vieira AR. TLR4 as a risk factor for periodontal disease: a reappraisal. J Clin Periodontol 2009;36: 279–86.
- Becker AE, de Boer OJ, van Der Wal AC. The role of inflammation and infection in coronary artery disease. Annu Rev Med 2001;52:289–97.
- Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–26.
- Xu XH, Shah PK, Faure E, Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103–8.
- Michelsen KS, Doherty TM, Shah PK, TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004;173:5901–7.
- Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004;34:328–34.
- Reismann P, Lichy C, Rudofsky G, Lack of association between polymorphisms of the toll-like receptor 4 gene and cerebral ischemia. J Neurol 2004;251:853–8.
- Zee RY, Hegener HH, Gould J, Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis. Stroke 2005;36:154–7.
- Lin YC, Chang YM, Yu JM, Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis 2005;180:305–9.
- Lalouschek W, Schillinger M, Hsieh K, Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events. Clin Chem Lab Med 2006;44:918–23.
- Yuan M, Xia J, Ma L, Lack of the Toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399ile in a Chinese Population. Int J Neurosci 2010;120:415–20.
- Liang YL, Xu ZQ, Kuang YF, Relation of Toll-like receptor 4 gene polymorphisms to artherosclerosis and cerebral infarction in Guangdong Han population. J Clin Neurol 2011;24:401–3.
- Džumhur A, Zibar L, Wagner J, Association studies of gene polymorphisms in toll-like receptors 2 and 4 in Croatian patients with acute myocardial infarction. Scand J Immunol 2012;75:517–23.
- Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet 2004;20:439–44.
- Moher D, Liberati A, Tetzlaff J, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9.
- Wells GA, Shea B, O'Connell D, The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute. www. ohri.ca /programs/clinical_epidemiology/oxford.asp. Accessed: October 20, 2011.
- Higgins JP, Thompson SG, Deeks JJ, Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
- Berkey CS, Hoaglin DC, Mosteller F, A random-effects regression model for meta-analysis. Stat Med 1995;14:395–411.
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer 1959;22:719–48.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clinic Trials 1986;7:177–88.
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
- Munafò MR, Flint J. Meta-analysis of genetic association studies. Trends Genet 2004;20:439–44.
- International HapMap Project. Available at: http: //hapmap. ncbi.nlm.nih.gov. Accessed: September 15, 2012.